CALL US AT 800-952-0521
Search
Close this search box.

FDA OKs Xeomin® for frown lines

Tuesday, August 02, 2011

Washington — The Food and Drug Administration (FDA) has approved Xeomin® (incobotulinumtoxinA, Merz Aesthetics) for temporary improvement of moderate to severe glabellar lines, Medscape Today reports.

According to a Merz statement, the approval is based on the results of two multicenter U.S. clinical trials involving 547 healthy adults. In both studies, Xeomin® injections significantly improved the appearance of glabellar lines in 30 days when compared with placebo. Headache was the most common adverse reaction observed.

Under the brand name Bocouture, Xeomin® is already approved in 14 European countries including Germany, the United Kingdom, France, Italy and Spain. It was FDA-approved in 2010 for the treatment of cervical dystonia and blepharospasm.

https://www.facialesthetics.org/blog/fda_oks_xeomin_for_frown_lines

Blog Categories

Related Posts